Front. Sports Act. Living Frontiers in Sports and Active Living Front. Sports Act. Living 2624-9367 Frontiers Media S.A. 10.3389/fspor.2023.1129320 Sports and Active Living Correction Corrigendum: Hidden figures: Revisiting doping prevalence estimates previously reported for two major international sport events in the context of further empirical evidence and the extant literature PetrócziAndrea 1 2 3 * CruyffMaarten 4 de HonOlivier 5 SagoeDominic 6 SaugyMartial 7 School of Life Sciences, Pharmacy and Chemistry, Faculty of Health, Science, Social Care and Education, Kingston University, London, United Kingdom Department of Movement Sciences, Faculty of Movement and Rehabilitation Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium Willibald Gebhardt Research Institute, University of Münster, Münster, Germany Faculty of Social Sciences, Utrecht University, Utrecht, Netherlands Doping Authority Netherlands, Capelle aan den IJssel, Netherlands Department of Psychosocial Science, University of Bergen, Bergen, Norway Research and Expertise in anti-Doping Sciences (REDs), Institute of Sport Sciences, University of Lausanne, Lausanne, Switzerland

Edited and Reviewed by: James Hopker, University of Kent, United Kingdom

 Correspondence: Andrea Petróczi A.Petroczi@kingston.ac.uk

Specialty Section: This article was submitted to Anti-doping Sciences & Integrity in Sport, a section of the journal Frontiers in Sports and Active Living

 31012023 2023 51129320 21122022 03012023 © 2023 Petróczi, Cruyff, de Hon, Sagoe and Saugy. 2023Petróczi, Cruyff, de Hon, Sagoe and Saugy

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 athlete performance enhancement doping randomised response technique prevalence single sample count prohibited substance elite sport Corrigendum on Hidden figures: Revisiting doping prevalence estimates previously reported for two major international sport events in the context of further empirical evidence and the extant literature By Petróczi A, Cruy M, de Hon O, Sagoe D and Saugy M (2022) Front. Sports Act. Living 4:1017329. doi: 10.3389/fspor.2022.1017329

Correction to Table/Figure

In the published article, there was an error in table 4 as published. There was an error in the estimated % of admitted doping (d) for H2: 0.3031 ± 0.0800 was erroneously listed for both the estimated % of admitted doping (d) and for the estimated % of noncompliance (nc). The correct value for the estimated % of admitted doping (d) is 0 and the value of the estimated % of noncompliance (nc) remains 0.3031 ± 0.0800. The corrected Table 4 and its caption Estimated use of prohibited performance enhancing substances and/or methods at WCA (12-month prevalence) appear below.

Estimated use of prohibited performance enhancing substances and/or methods at WCA (12-month prevalence).

Model fit Estimated % of admitted doping (d) Estimated % of noncompliance (nc)p = 1.1E-16
H Log-likelihood AIC BIC
H0 −1854.0342 3708.07 3708.07
H1 −1853.9311 3709.86 3714.95 0.0132 ± 0.0576 0
H2 −1819.0675 3642.14 3652.32 0 0.3031 ± 0.0800
H3 −1819.5104 3643.02 3653.21 0.0132 ± 0.0576 0.0699 ± 0.0201
H4 −1799.2650 3602.53 3612.72 0.2124 ± 0.0873 0.3190 ± 0.0562
H5 −1853.9311 3711.86 3722.05 0.0132 ± 0.0576 0

In Figure 3: Comparison of doping prevalence estimates for WCA and PAG between the two survey formats, and with literature evidence. Data extracted from Table 1 using the most relevant figure (i.e., elite level and current/last season/past 12 months) when multiple estimates are reported. In the figure legend ‘ABP Blood doping WAC 2021’ should read as ‘ABP Blood doping WCA 2011’.

Incorrect Supplementary Material

In the published article, there was an error in Supplementary Material 2: Detailed prevalence and noncompliance estimations, Table 2.1: Detailed prevalence and noncompliance estimations for WAC and PAG, 2011. Incorrect values were reported for ‘Estimation’. The correct material statement appears below.

Model WAC doping use PAG doping use PAG nutritional supplement use
Estimation d Lowest 0.1251 0.0290 0.0103
  Highest 0.2997 0.1836 0.1611
  Midpoint of multiplied Cis 0.2124 0.1063 0.0857
CI (d) 0.0872 0.0773 0.0754
nc Lowest 0.2628 0.0927 0.0531
  Highest 0.3752 0.1043 0.1755
  Midpoint of multiplied Cis 0.3190 0.0985 0.1143
CI (nc) 0.0562 0.0058 0.0612
D d*nc Lowest 0.03287628 0.00268714 0.00054693
  Highest 0.11244744 0.019156824 0.02827305
  Midpoint of multiplied Cis 0.07266186 0.010921982 0.01440999
d* (1-nc) Lowest 0.07816248 0.02597414 0.00849235
  Highest 0.22093884 0.166587624 0.15254559
  Midpoint of multiplied Cis 0.14955066 0.096280882 0.08051897
NC (1-d)*nc Lowest 0.18403884 0.075647624 0.04454559
  Highest 0.32826248 0.101314104 0.17369235
  Midpoint of multiplied CIs 0.25615066 0.088480882 0.10911897
(1-d)* (1-nc) Lowest 0.43754744 0.731216824 0.69167305
  Highest 0.64497628 0.881027140 0.93714693
  Midpoint of multiplied CIs 0.54126186 0.806121982 0.81440999

The authors apologize for these error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.